Compare Natera Inc. Common Stock (NTRA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ross Stores, Inc. — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Ross Stores, Inc. trades at $230.66 (market cap $72.09B). The key difference: Ross Stores, Inc. is the larger of the two by market cap, and Ross Stores, Inc. pays a 0.79% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ross Stores, Inc. for 48 Days on average.
| NTRA | ROST | |
|---|---|---|
Market Cap | $57.03B | $72.09B |
Volume | 1,131,157 | 1,593,708 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $255.23 |
52-Week Low | $179.42 | $155.21 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $56.18B | $72.55B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Ross Stores (ROST) trades at $230.57, up 2.09% today, showing strong momentum with three consecutive earnings beats. The stock faces technical headwinds with a bearish signal but maintains robust fundamentals including 42.63% ROE and 10.85% net margins. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents a compelling investment case with analyst consensus target of $274.14 (19% upside) and strong institutional support. However, near-term technical weakness and competitive pressures in discount retail require monitoring. The company's consistent earnings outperformance and expanding margins support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
